(Press-News.org) A large study from Denmark and Norway published by The BMJ today sheds more light on the risk of rare blood clots in adults receiving their first dose of the Oxford-AstraZeneca covid-19 vaccine.
The findings show slightly increased rates of vein blood clots including clots in the veins of the brain, compared with expected rates in the general population. However, the researchers stress that the risk of such adverse events is considered low.
Cases of rare blood clots in people who have recently received their first dose of the Oxford-AstraZeneca covid-19 vaccine have been reported. Whether these cases represent excess events above expected rates in the general population has, however, been debated.
Both the UK and European medicine regulators say the benefits of the Oxford-AstraZeneca vaccine still outweigh the risks. Denmark and Norway have suspended use of the vaccine and several other countries have opted to suspend its use in certain age groups.
To explore this further, researchers based in Denmark and Norway set out to compare nationwide rates of blood clots and related conditions after vaccination with the Oxford-AstraZeneca vaccine with those in the general populations of the two countries.
Their findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca covid-19 vaccine in Denmark and Norway from February 2021 through to 11 March 2021.
Using national health records, they identified rates of events, such as heart attacks, strokes, deep vein blood clots and bleeding events within 28 days of receiving a first vaccine dose and compared these with expected rates in the general populations of Denmark and Norway.
In the main analysis, the researchers found 59 blood clots in the veins compared with 30 expected, corresponding to 11 excess events per 100,000 vaccinations. This included a higher than expected rate of blood clots in the veins of the brain, known as cerebral venous thrombosis (2.5 events per 100,000 vaccinations).
However, they found no increase in the rate of arterial clots, such as heart attacks or strokes.
For most remaining outcomes, results were largely reassuring, with slightly higher rates of less severe events such as thrombocytopenia (a condition related to low blood platelet levels), clotting disorders and bleeding, which they say could be influenced by increased surveillance of vaccine recipients.
This is an observational study, so can't establish cause, only correlation. And the researchers point to some limitations, such as a lack of data on underlying risk factors for clotting and the possibility that their results may not apply to other ethnicities.
However, strengths include the large population based approach, using reliable national registry data and near complete follow-up of participants.
They conclude that "the absolute risks of venous thromboembolic events described in this study are small, and the findings should be interpreted in the context of the benefits of covid-19 vaccination at both the societal and the individual level."
In a linked editorial, BMJ editors Rafael Perera and John Fletcher point out that covid-19 is itself associated with cerebral venous thrombosis and say vaccination remains overwhelmingly the safest option.
"The choice we nearly all face is between eventual SARS CoV2 infection or vaccination. The Astra-Zeneca vaccine is clearly a good choice, despite the likely risks reported in this study," they write.
"Quantifying the comparative risk associated with other vaccines is now a research (and public health) priority," they conclude.
In a linked opinion, Professor Paul Hunter at the University of East Anglia, says this study improves our understanding of the population risk of thrombotic events after the Oxford-AstraZeneca vaccine, but it does not change the conclusions of the UK and European medicine regulators that the benefits of the Oxford-AstraZeneca vaccine far outweigh its risks for most age groups.
"Those countries that delayed their own vaccination programmes at a time of high transmission rates by declining to use available Oxford-AstraZeneca vaccines should know that their decision will have contributed to an increase in the number of avoidable deaths from covid-19," he argues.
INFORMATION:
Externally peer reviewed? Yes (research), No (linked editorial and opinion)
Evidence type: Observational
Subjects: People
The new Danish-Norwegian study is the first study to document possible adverse events in relation to the COVID-19 vaccine Vaxzevria? from AstraZeneca, in which all vaccine recipients have been followed systematically, as opposed to previous studies, which have relied primarily on reported adverse reactions.
The new study was a cooperation between Danish and Norwegian research institutions.
- In this study, we were able to identify all hospital contacts among vaccinated persons by utilising the unique Danish and Norwegian health registers. This ensures that we get a comprehensive of the rate of adverse reactions. ...
Some clinicians are concerned that post-traumatic stress disorder (PTSD) diagnosis has risen throughout Western society since the late 1980s. Is this correct? And if so, has the true incidence of PTSD really spiralled out of control, or has it simply become overdiagnosed?
Experts debate the issue in The BMJ this week.
PTSD is a serious and uncommon condition resulting from severe trauma, but it has unhelpfully become an umbrella term incorporating other disorders and normal reactions to stress, argue John Tully at the University of Nottingham and Dinesh Bhugra at King's College London's Institute for Psychiatry, Psychology & Neuroscience (IoPPN).
Estimates of lifetime population prevalence are now about 7% in the US (26 million cases) and 5% in other high income countries. ...
Admission to an intensive care unit (ICU) is associated with a small increased risk of future suicide or self-harm after discharge compared with non-ICU hospital admissions, finds a study published in The BMJ today.
The findings are particularly relevant during the covid-19 pandemic, as the number of ICU admissions around the world reach all-time highs.
The findings show that survivors of critical illness who later died by suicide or had self-harm events tended to be younger with a history of psychiatric illness, and had received invasive life support.
The researchers stress that the overall risk is still very low, but say knowledge of these factors "might allow for earlier intervention to potentially reduce this important public health problem."
Survival after ...
Israel is the first country to report national data on the Pfizer-BioNTech vaccine, with observational analysis showing that two doses provide more than 95% protection against COVID-19 infection, hospitalisation, and death, including among the elderly, at a time when the B.1.1.7 variant was the dominant strain.
A single dose of the vaccine was associated with 58% protection against infection, 76% against hospitalisation, and 77% against death, emphasising the importance of fully vaccinating adults.
Challenges to controlling the pandemic remain, including uncertainty about ...
R21/Matrix-M becomes the second malaria vaccine candidate ever to start a phase III licensure trial
This builds on the recent finding of high level efficacy of this vaccine in a phase IIb trial in children in Burkina Faso, published today in The Lancet
The first phase III trial doses were administered by the team at the Malaria Research and Training Centre, Bamako, Mali, one of five trial sites across West and East Africa
The malaria vaccine was designed at the Jenner Institute, University of Oxford, who have partnered with the Serum Institute of India for commercial development
The annual death toll from ...
A new mutation found in a gene associated with an increased risk of atrial fibrillation poses a significantly increased risk for heart failure in Black people.
The discovery, made by researchers at the University of Illinois Chicago, could change current guidelines that recommend against genetic testing in people with atrial fibrillations, also known as AFib.
"We found that this new variant confers a significantly increased risk in African Americans, and this mutation has a 50% chance of being passed on to offspring," said Dr. Dawood Darbar, UIC professor of medicine and pharmacology at the College of Medicine. "Since it increases risk for heart failure, it would be wise to test people with atrial fibrillation to see if ...
According to a new study published in the journal Research in Social and Administrative Pharmacy, hospitals that participate in the 340B Drug Pricing Program provide more medication access services -- which are services that help remove barriers to accessing necessary medications -- than comparably sized non-340B hospitals.
The University of Illinois Chicago researchers who conducted the study, which included a survey of available services sent to a nationally representative sample of hospitals across the U.S., suggest that 340B participating hospitals may be better positioned to create and administer programs that support patients who are uninsured ...
Older people with kidney disease have a higher risk of dementia, and the risk increases with the rate and stage of kidney function decline. That is according to a large observational study by researchers at Karolinska Institutet in Sweden, published in the journal Neurology. The findings stress the significance of screening and monitoring for dementia in persons with kidney disease, the researchers say.
"Our study underscores the importance of low kidney function as a possible under-recognized risk factor for dementia," says co-author Juan Jesus Carrero, professor at the Department ...
With increased media attention and political campaigns focusing on the gender pay gap, the fact that women -- on average -- are paid less than men, has become an important public discussion. While much of the focus has been on the corporate sector, a new study that looked at executive compensation at nonprofit organizations found that women earn 8.9% less than men with the gap becoming greater when there is room for salary negotiations.
The study co-authored by Curtis Hall, PhD, an associate professor in Drexel University's LeBow College of Business; Andrew R. Finley, assistant professor at the Robert Day School of Economics and Finance at Claremont McKenna College; and LeBow College of Business doctoral student Amanda R. Marino, analyzed data from IRS ...
A multidisciplinary team of researchers from INRAP, CNRS, the universities of Ottawa, Rennes 2, Toulouse III Paul Sabatier and the Max Planck Institute has recognised the soldiers of the last battles of the siege of Rennes in 1491. These are the only witnesses of the forces involved in the conflict between the armies of Duchess Anne of Brittany and the King of France. This research and its methodology are currently the subject of two articles in the PLOS ONE review.
The excavation of the Jacobins convent in Rennes
From 2011 to 2013, a team from INRAP excavated the convent of the Jacobins, site of the future congress centre in Rennes Métropole, giving rise to numerous scientific ...
